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OBJECTIVE—To examine the impact of withdrawing rosiglitazone and ramipril medication
on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and
rosiglitazone Medication (DREAM) trial.
RESEARCH DESIGN AND METHODS—The 3,366 DREAM subjects at trial end who
had not developed diabetes while taking double-blind study medication were transferred to
single-blindplacebofor2to3monthsbeforeundergoinganoralglucosetolerancetest.Glycemic
status was analyzed for the trial plus washout period and for the washout period alone.
RESULTS—Following median (interquartile range) 71 (63–86) days drug withdrawal, overall
glycemic status remained modestly improved in those allocated ramipril during the trial with an
11% increase in regression to normoglycemia, compared with placebo. In those previously
allocated rosiglitazone, glycemic status remained substantially improved with a 49% reduction
of new-onset diabetes or death and a 22% increase in regression to normoglycemia, compared
with placebo. However, during the washout phase alone the incidence of diabetes or death was
identical for those allocated previously to ramipril or placebo, or to rosiglitazone or placebo.
CONCLUSIONS—Inpeopleallocatedtoramiprilcomparedwiththosenotallocatedramipril
during the trial, the postwashout normoglycemia incidence was higher. In people allocated to
rosiglitazone compared with those not allocated rosiglitazone during the trial, the postwashout
incidence of diabetes was signiﬁcantly lower and the incidence of normoglycemia was higher.
During the washout period, diabetes incidence was the same for ramipril versus placebo and for
rosiglitazone versus placebo. Rosiglitazone delays disease progression during treatment but the
process resumes at the placebo rate when the drug is stopped.
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T
ype 2 diabetes prevention is a major
p u b l i ch e a l t hi s s u e .T h eD i a b e t e s
REductionAssessmentwithramipril
and rosiglitazone Medication (DREAM)
trial(1)showedthatthenew-onsetdiabe-
tes rate in people with impaired glucose
tolerance (IGT) and/or impaired fasting
glucose (IFG) can be slowed substan-
tially (60% relative to placebo) by the
thiazolidinedione rosiglitazone (2) but
not by the ACE inhibitor ramipril (3).
The rosiglitazone results were similar to
thoseseenintwotrialswiththenowwith-
drawn thiazolidinedione troglitazone
(4,5). DREAM also showed that both ro-
siglitazoneandramiprilincreasedthe rate
of regression to normal glucose tolerance
(2,3).
Because type 2 diabetes is a progres-
sive disorder (6), it is of interest to know
whether an intervention that delays dia-
betesonsetis1)maskingdiabetes appear-
ance by suppressing glucose levels, 2)
slowing diabetes development only while
it is being administered, or 3) has sus-
tained beneﬁt even after withdrawal.
These possibilities can be distinguished
by washing out the intervention and
then reassessing glycemic status (Fig. 1).
If diabetes was being masked, postwash-
out diabetes incidence in the intervention
group would exceed that in the placebo
group andthe overall (trial plus washout)
diabetesprevalenceinbothgroupswould
be similar (Fig. 1, scenario 1). If the un-
derlying disease process only slowed dur-
ing intervention, postwashout diabetes
incidence would be similar in the inter-
vention and placebo groups, with the
overallprevalenceofdiabetesinthegroup
formerly receiving the intervention re-
maining lower than in the placebo group
(Fig. 1, scenario 2). Finally, if the inter-
vention had a sustained effect after drug
withdrawal, both the washout incidence
and the overall diabetes prevalence in the
groupformerlyreceivingtheintervention
wouldbelowerthanintheplacebogroup
(Fig. 1, scenario 3). Follow-up data from
the truncated troglitazone arm of the Di-
abetes Prevention Program (DPP) sug-
gested that scenario 2 may be the case for
thiazolidinediones (5).
We conducted a prospective 2- to
3-month post-trial medication washout
to evaluate the impact on the new-onset
type 2 diabetes rate in consenting DREAM
trial participants who at trial endhadnot
developed diabetes, were taking their
double-blind study medication, and un-
derwent an oral glucose tolerance test
(OGTT).
RESEARCH DESIGN AND
METHODS—The design and primary
results of the DREAM trial have been
published (1–3). Between July 2001 and
August 2003, 5,269 participants aged
30 years or more with impaired fasting
plasma glucose (FPG; $6.1 but ,7.0
mmol/L) and/or IGT (2-h post 75 g oral
g l u c o s el o a dp l a s m ag l u c o s e$7.8 but
,11.1mmol/L)wereallocatedatrandom
toreceiveramipril(titratedtoamaximum
of 15 mg) or matching placebo and, si-
multaneously, rosiglitazone (titrated to a
maximum of 8 mg) or matching placebo,
inatwo-by-twobalancedfactorialdesign.
ParticipantshadOGTTsdoneafter2years
and at ﬁnal visit, and at other yearly visits
if FPG or HbA1c values were elevated (2),
andwerefollowedforamedianof3years.
All participants provided informed written
consent for the whole study, including the
washout phase.
Consenting participants who under-
went an OGTT at their last study visit,
who had not developed diabetes, and
who were taking their study medication
were entered into the post-trial washout.
They were given single-blind placebo
rosiglitazone and ramipril medication
and scheduled for an OGTT 2 to 3
months later. No other clinical assess-
mentsweredoneattheendofthisperiod.
The primary composite outcome for
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ORIGINAL ARTICLEthewashoutwasthesameasthemaintrial
(new-onset diabetes or death), but the
diagnosis of diabetes was based on one,
not two, successive abnormal OGTTs or
FPG values $7.0 mmol/L. As before, de-
velopment of diabetes in an individual
was accepted if a physician outside the
study diagnosed diabetes on the basis
of a FPG level $7.0 mmol/L or a non-
FPG level $11.1 mmol/L and had pre-
scribed an antidiabetic agent.
Statistical analysis
Data were collected and analyzed at the
Population Health Research Institute,
McMasterUniversity,usinganintention-
to-treat approach according to marginal
groups: ramipril versus placebo and ro-
siglitazone versus placebo. Participants
who entered the washout phase but who
did not return for an OGTT and whose
postwashout diabetes status was un-
known were assumed not to have de-
velopeddiabetes.Differencesintrial-end
prewashout characteristics by prior ran-
domization were compared using t tests
for continuous variables and x
2 tests for
categoricalvariables.Hazardratios(HRs)
and 95% CIs for the effect of prior treat-
ment with each study drug (stratiﬁed by
the other drug) on the primary outcome,
and on the secondary outcome of regres-
sion to normoglycemia, were calculated
using Cox proportional hazards models.
Possible statistical interactions between
ramipril and rosiglitazone treatments
w e r ea s s e s s e db yt h ei n c l u s i o no fa ni n -
teraction term in the models. Trial plus
washout analyses were done for all ran-
domized participants from the time of
randomizationuntiltheendofthewash-
out period. Participants who did not en-
ter the washout phase were analyzed
according to their trial-end glycemic sta-
tus. Additional washout alone analyses
were restricted to those participants
whoenteredthewashoutperiod.Median
changes in fasting and 2-h plasma glucose
levelsduringthewashoutphasewerecom-
pared according to prior treatment with
eachstudydrugorrespectiveplacebousing
Wilcoxon signed rank tests (with no ad-
justment for multiple testing).
RESULTS
Subject disposition
Of the 5,269 randomized participants
the primary outcome occurred by trial
end in 995, comprising the 992 reported
previously (2,3) plus 3 more with de-
layed reports. An additional 907 people
were ineligible for the washout because
they had no ﬁnal-visit OGTT (n =6 4 )o r
were no longer taking study medication
(n = 843). Of the eligible 3,367, 105 de-
clined to participate. The 3,262 (96.9%)
participants completing the washout pe-
riod were followed for a median (inter-
quartilerange[IQR])of71(63–86)days.
When compared with the 105 individ-
ualswhodeclinedparticipation,thesein-
dividuals had a similar duration of trial
follow-up, age, sex, weight, waist-to-hip
ratio, blood pressure, and mean FPG
level (P all . 0.1), but lower 2-h post-
challengeglucosevalue(7.13mmol/Lvs.
7.77 mmol/L; P = 0.0024).
Trial-end characteristics
Table1liststheparticipantcharacteristics
at trial end according to their prior allo-
cation to ramipril or placebo and to rosi-
glitazone or placebo. These reﬂect the
Figure 1—Three possible scenarios show-
ing the relative proportions of subjects with
new-onset diabetes at the end of a diabetes
prevention trial, after the trial plus a drug
washout period, and after the washout period
alone. Scenario 1 illustrates a treatment that
merely masks the appearance of diabetes by
suppressing glucose levels. Scenario 2 demon-
strates slowing the development of diabetes
while the treatment is being given. Scenario 3
showssustainedbeneﬁtevenafterthetreatment
has been withdrawn.
Table 1—Demographic, clinical, and biochemical characteristics of the 3,367 subjects without diabetes who entered
the drug washout period
All Ramipril Placebo P Rosiglitazone Placebo P
n
Entering washout 3,367 1,677 1,690 1,833 1,534
Completing washout 3,262 (96.9%) 1,632 (97.3%) 1,630 (96.5%) 1,773 (96.7%) 1,489 (97.1%)
Female 1,897 (58.2%) 972 (59.6%) 925 (56.8%) 0.11 1,003 (56.67%) 894 (60.0%) 0.046
Follow-up to trial end (years) 3.2 6 0.5 3.2 6 0.5 3.2 6 0.5 0.28 3.2 6 0.5 3.2 6 0.5 0.89
Mean age at trial end (years) 58.1 6 10.7 58.1 6 10.8 58.0 6 10.6 0.83 57.9 6 10.5 58.3 6 10.9 0.30
FPG (mmol/L) 5.56 6 0.72 5.54 6 0.70 5.59 6 0.74 0.029 5.46 6 0.69 5.69 6 0.74 ,0.0001
2HPG (mmol/L) 7.13 6 1.96 7.04 6 1.94 7.22 6 1.98 0.013 6.76 6 1.82 7.57 6 2.03 ,0.0001
BP (mmHg)
Systolic 129.2 6 17.1 127.0 6 17.1 131.5 6 16.8 ,0.0001 128.4 6 16.8 130.2 6 17.4 0.0025
Diastolic 78.4 6 10.6 77.2 6 10.7 79.6 6 10.3 ,0.0001 77.7 6 10.4 79.2 6 10.6 ,0.0001
BMI (kg/m
2)3 1 . 0 6 5.7 31.0 6 5.7 31.0 6 5.7 0.94 31.6 6 5.7 30.4 6 5.6 ,0.0001
Weight (kg) 85.3 6 19.4 85.1 6 19.3 85.5 6 19.5 0.56 87.3 6 19.7 83.0 6 18.7 ,0.0001
Waist/hip
Male 0.96 6 0.08 0.96 6 0.08 0.96 6 0.08 0.58 0.96 6 0.08 0.96 6 0.07 0.62
Female 0.87 6 0.12 0.87 6 0.13 0.87 6 0.10 0.60 0.86 6 0.13 0.88 6 0.11 0.0075
Categorical variables are expressed as n (%) and continuous variables as mean 6 1S D .
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DREAM trial drug washoutglycemic impact of these therapies before
commencing the washout phase. Partici-
pants allocated previously to ramipril(n=
1,632), compared with those allocated
to placebo (n = 1,630), had lower fasting
and 2-h postchallenge plasma glucose
values and lower systolic and diastolic
blood pressure values. Participants allo-
cated previously to rosiglitazone (n =
1,773), compared with those allocated
to placebo (n = 1,489), had lower fasting
and 2-h postchallenge plasma glucose
values and lower systolic and diastolic
blood pressure values. They were also
less likely to be women and were heavier,
and the females had a lower waist-to-hip
ratio.
Ramipril outcomes
At trial-end plus washout, the proportion
of participants in whom the primary out-
come had occurred (Fig. 2A and Table 2)
did not differ between those allocated to
ramipril or to placebo (24.9 vs. 25.8%,
respectively; P = 0.45); the proportion of
participants regressing to normoglyce-
mia was greater (HR 1.11 [95% CI
1.01–1.21]; P = 0.031) for those allo-
cated to ramipril (36.0%) compared
with placebo (33.2%). During the wash-
out period alone, both the primary and
secondaryoutcomeoccurredatthesame
rate in both groups (10.6 vs. 9.7%, P =
0.32; and 23.0 vs. 22.7%, P =0 . 6 6 ,
respectively).
Rosiglitazone outcomes
At the end of the trial plus washout, the
proportion of participants in whom the
primary outcome had occurred (Fig. 2B
and Table 2) was less (HR 0.51 [95% CI
0.45–0.57]; P , 0.0001) for those allo-
cated to rosiglitazone (19.0%) compared
with placebo (31.7%); the proportion of
participants regressing to normoglycemia
was greater (HR 1.22 [1.11–1.34]; P ,
0.0001) for those allocated to rosiglitazone
(39.2%) compared with placebo (30.0%).
During the washout period alone, both the
primary and secondary outcome occurred
at the same rate in both groups (10.5 vs.
9.8%,P=0.59;and21.5vs.23.8%,P=0.33,
respectively).
Postwashout fasting and 2-h
plasma glucose levels
At the end of the washout, there was no
difference in either fasting or 2-h post-
challenge median plasma glucose levels
between people originally allocated to
ramipril versus placebo (Table 3). At the
same time median FPG levels did not dif-
fer between those allocated to rosiglita-
zone or placebo, despite lower FPG levels
in the rosiglitazone group at trial end
(Table 3). This was the result of a greater
increase in FPG levels during the wash-
out in participants formerly on rosi-
glitazone versus placebo (0.30 vs. 0.10
mmol/L, respectively; P , 0.0001).
Conversely,2-hpostchallengeplasmaglu-
cose levels remained lower after the wash-
out (7.1 vs. 7.4 mmol/L; P = 0.005)
despite a greater increase in the rosiglita-
zone group (0.5 mmol/L) compared with
the placebo group (0.0 mmol/L; P ,
0.0001).
Interaction effects
No statistical interactions were observed
between ramipril and rosiglitazone with
respect to FPG levels, 2-h plasma glucose
levels, or glycemic status at the end of the
trial plus washout or during the washout
period alone.
Further analyses
No differences were seen in the results for
individualsenteringthestudywithIFGas
opposed to IGT.
CONCLUSIONS—The DREAM study
primary outcome (new-onset diabetes or
death)resultsremainedessentiallysimilar
when reanalyzed after a median 71-day
study medication washout period. With
respect to the washout period itself, be-
cause ramipril did not reduce diabetes
incidence in the main trial (2) it is not
surprising that the postwashout new-
onsetdiabetesratesdidnotdifferbetween
thoseallocatedramiprilorplaceboduring
the trial. The lack of any differential im-
pact on post-trial diabetes incidence be-
tween those allocated rosiglitazone or
placeboduringthetrial,despitethemajor
within-trial reduction in diabetes inci-
dence (3), suggests that this agent does
not have a sustained effect on the under-
lying disease pathophysiology.
The incidence of diabetes after ther-
apy cessation with either of the agents
evaluated did not differ from the inci-
dence observed with placebo. These ﬁnd-
ings suggest that the underlying disease
process is slowed only while the inter-
vention is being given (scenario 2). The
Figure 2—Proportions of subjects with new-
onset diabetes at the end of the trial, after the
trial plus drug washout, and after the washout
period (median 71 days) alone for ramipril vs.
placebo(A)and rosiglitazone vs.placebo arms
of the trial (B).
Table 2—HRs (95% CI) for development of diabetes or death at trial end, at trial end plus washout, and during washout period alone
for the ramipril vs. placebo and for the rosiglitazone vs. placebo arms of the trial
Ramipril Placebo HR (95% CI) P Rosiglitazone Placebo HR (95% CI) P
Primary outcome
Trial end 476/2,623 519/2,646 0.91 (0.80–1.03) 0.14 309/2,635 686/2,634 0.40 (0.35–0.46) ,0.0001
Trial + washout 654/2,623 683/2,646 0.95 (0.84–1.08) 0.45 501/2,635 836/2,634 0.51 (0.45–0.57) ,0.0001
Washout alone 178/1,677 164/1,690 1.12 (0.90–1.38) 0.32 192/1,833 150/1,534 1.06 (0.86–1.32) 0.59
Secondary outcome*
Trial end 1,117/2,623 1,013/2,646 1.17 (1.07–1.27) 0.0002 1,329/2,635 801/2,634 1.69 (1.55–1.85) ,0.0001
Trial + washout 944/2,623 878/2,646 1.11 (1.01–1.21) 0.031 1,032/2,635 790/2,634 1.22 (1.11–1.34) ,0.0001
Washout alone 164/714 183/807 1.05 (0.85–1.30) 0.66 144/669 203/852 0.90 (0.73–1.12) 0.33
*Regression to normoglycemia.
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The DREAM Trial Investigatorsfact that most (but not all) of their effects
on glucose levels disappear with drug
discontinuation also suggests that under-
lying b-cell defects are not reversed or
repaired and that the minor metabolic ef-
fects of ramipril and the profound effects
of rosiglitazone are likely secondary to in-
creased sensitivity to insulin.
The rosiglitazone results are consis-
tent with the observations made in a sim-
ilar population of 585 people with IGT
who took troglitazone for a median pe-
riod of 0.9 years in the DPP trial (5).
When compared with placebo, troglita-
zone reduced the incidence of diabetes
by 75% while it was being taken, but
whendiscontinued(becauseofemerging
concerns about liver toxicity) diabetes
incidence was similar to, but not greater
than, that in the placebo group. There-
fore, in the context of the full 3-year fol-
low of the DPP, study participants who
had taken troglitazone for 0.9 years were
only ;17% less likely to have developed
diabetes. By contrast, these ﬁndings are
inconsistent with a study in women
with a history of gestational diabetes (4)
where troglitazone reduced the inci-
dence of diabetes by 55% compared
with placebo while it was being taken,
but the effect persisted during an
8-month washout period. Postwashout
glucose tolerance testing, however, was
onlydoneinasubsetofrandomizedpeo-
ple who completed the trial without di-
abetes and who then returned after the
washout. The possibility that responders
were more likely to return for reassess-
ment than nonresponders cannot be
excluded.
The prospectively planned DREAM
washout was completed while partici-
pants were taking single-blind placebo
medication. Moreover, 97% of eligible
participants completed this phase of the
study with completion rates the same
inthosepreviouslyonactivetherapies or
placebo (Table 1). These strengths sup-
porttherobustness of the DREAM wash-
out ﬁndings but there are several
limitations. First, the ;10% primary
outcome incidence during a median
washout of 71 days is higher than ex-
pected given the 26% 3-year incidence
in the rosiglitazone placebo group dur-
ing the trial (Fig. 2B). This is likely be-
cause of the fact that during the washout
phase incident diabetes was based on
only a single abnormal fasting or 2-h
plasma glucose level as opposed to two
successive abnormal values during the
trial. Because of regression to the mean
(7), many of those classiﬁed with diabe-
tes based on a single abnormal glucose
value during washout would not have
hadthisdiagnosisconﬁrmedonasecond
test. Similar discrepancies in post-trial
diabetes incidence rates have been noted
inotherdiabetespreventiontrials,which
reported high diabetes incidence rates
based on one abnormal glucose value
following a short washout phase (5,8).
Any overestimate of the absolute inci-
dence of diabetes would, however, affect
all treatment groups to the same extent
so should not invalidate between-group
comparisons. A second limitation is the
relatively short washout period of a me-
dian 71 days. This may have been insuf-
ﬁcient to totally wash out rosiglitazone,
which may require a longer period of
study medication. Finally, the effect of
the washout on other secondary mea-
surements such as liver function tests,
blood pressure, body weight, and edema
was not assessed.
In summary, rosiglitazone delays dis-
ease progression during treatment, but
the process resumes at the placebo rate
when the drug is stopped, as has been
seen previously with metformin (9). Addi-
tional longer-term assessments of glucose
tolerance in epidemiologic follow-up
studies may yield further insights in the
context of the effect of these interventions
onthenaturalhistoryofIFG,IGT,andtype
2 diabetes. At this time the data indicate
that rosiglitazone can substantially reduce
theincidenceoftype2diabeteswhileitis
being administered, but this effect is not
sustained when the drug is withdrawn.
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Ramipril Placebo
P
Rosiglitazone Placebo
P n Median IQR n Median IQR n Median IQR n Median IQR
Fasting glucose
Baseline 2,623 5.9 5.4–6.3 2,646 5.9 5.4–6.4 0.45 2,635 5.9 5.4–6.4 2,634 5.9 5.4–6.3 0.52
Trial end 2,418 5.7 5.2–6.3 2,440 5.7 5.2–6.5 0.033 2,431 5.5 5.1–6.1 2,427 5.9 5.3–6.5 ,0.0001
Washout 1,630 5.7 5.2–6.2 1,628 5.7 5.3–6.2 0.090 1,769 5.7 5.2–6.2 1,489 5.7 5.2–6.2 0.72
2-h Glucose
Baseline 2,623 8.6 8.0–9.6 2,646 8.8 8.0–9.8 0.064 2,635 8.7 8.0–9.7 2,634 8.7 8.0–9.7 0.85
Trial end 2,032 7.1 5.8–8.7 2,033 7.3 5.9–8.9 0.020 2,168 6.7 5.6–8.3 1,897 7.7 6.2–9.4 ,0.0001
Washout 1,624 7.2 5.9–8.6 1,610 7.3 6.0–8.9 0.052 1,754 7.1 5.9–8.6 1,480 7.4 6.0–9.0 0.0051
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